Comparative Pharmacology
Head-to-head clinical analysis: LENVIMA versus PONLIMSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENVIMA versus PONLIMSI.
LENVIMA vs PONLIMSI
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. It inhibits angiogenesis, tumor growth, and progression by blocking these receptor tyrosine kinases.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancerIn combination with everolimus, for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapyFirst-line treatment of patients with unresectable hepatocellular carcinomaOff-label: in combination with pembrolizumab for advanced endometrial carcinoma
FDA-approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.Off-label: Investigational in acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors.
24 mg orally once daily for differentiated thyroid carcinoma; 18 mg orally once daily plus everolimus 5 mg orally once daily for renal cell carcinoma; 12 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks for endometrial carcinoma; 8 mg orally once daily (or 10 mg for patients with body weight ≥60 kg) plus pembrolizumab 200 mg intravenously every 3 weeks for hepatocellular carcinoma.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 28 hours, supporting once-daily dosing.
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Lenvatinib is primarily metabolized by CYP3A4 and aldehyde oxidase (AO). The major metabolite is desmethyl-lenvatinib (M2), which is formed by CYP3A4. Minor metabolites include lenvatinib N-oxide (M1) and other oxidative products.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8. Metabolites are mainly excreted in feces (77%) and urine (17%), with less than 1% as unchanged drug.
Approximately 71% of the dose is excreted in feces (34% as unchanged drug) and 25% in urine (0.4% as unchanged).
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
99.3% bound to human plasma proteins (primarily albumin, with minor binding to alpha-1-acid glycoprotein).
98% bound to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 1.1 L/kg, indicating extensive extravascular distribution.
0.8 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 72% relative to an intravenous reference dose.
Oral: 75% (range 60-85%); IV: 100%.
CrCl ≥30 mL/min: no adjustment. CrCl <30 mL/min: not recommended.
No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or ESRD.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 5 mg if starting dose is 24 mg, by 2 mg if starting dose is 18 mg, by 2 mg if starting dose is 14 mg, by 1 mg if starting dose is 10 mg. Child-Pugh C: not recommended.
Child-Pugh A: No dose adjustment. Child-Pugh B: Reduce dose to 75 mg IV. Child-Pugh C: Not recommended.
Not approved for pediatric patients; safety and efficacy not established.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment based on age alone; monitor renal function and consider age-related decline in CrCl.
No specific dose adjustment recommended. Monitor for increased toxicity due to age-related renal and hepatic function decline.
None
No FDA black box warning at the time of approval.
["Hypertension (monitor blood pressure and manage with antihypertensives)","Cardiac dysfunction (risk of decreased left ventricular ejection fraction)","Arterial thromboembolic events","Hepatotoxicity (elevated liver enzymes, risk of hepatic encephalopathy in HCC)","Renal toxicity (proteinuria, renal impairment)","Diarrhea (may cause severe dehydration)","Hypothyroidism (monitor thyroid function)","Wound healing complications (consider interruption before surgery)","Posterior reversible encephalopathy syndrome (PRES)"]
Thrombocytopenia (manage with dose interruptions/reductions and supportive care), gastrointestinal toxicities (diarrhea, nausea, vomiting), hepatotoxicity (monitor liver function tests), increased risk of infections, and embryo-fetal toxicity.
["None known"]
Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) due to reduced efficacy; hypersensitivity to ponlimsi or any of its excipients.
Data Pending Review
Data Pending Review
Avoid grapefruit and grapefruit juice as they may increase LENVIMA concentrations. No other specific food interactions known.
Avoid grapefruit and grapefruit juice. No other significant food interactions. Take with or without food, but swallow tablets whole with water.
Lenvatinib is teratogenic and embryotoxic in animal studies. It is contraindicated in pregnancy. Risk in first trimester: high risk of congenital malformations including skeletal and cardiovascular anomalies. Second and third trimester: risk of fetal growth retardation, oligohydramnios, and fetal demise due to antiangiogenic effects.
First trimester: Based on animal studies and limited human data, there is a potential risk of fetal malformations including skeletal and cardiovascular anomalies. Second and third trimesters: May cause fetal growth restriction and oligohydramnios due to effects on placental perfusion. Avoid use in pregnancy unless benefit outweighs risk.
No data on human breast milk; animal studies show excretion into milk. M/P ratio unknown. Discontinue breastfeeding during therapy and for at least 1 month after last dose due to potential for serious adverse reactions in breastfed infants.
No human data available on excretion into breast milk. M/P ratio not established. Due to unknown risk, advise against breastfeeding during therapy and for at least 2 weeks after last dose.
No established dose adjustments in pregnancy as use is contraindicated. Pharmacokinetic changes pregnancy may alter metabolism but no data; dose reduction not recommended. If exposure occurs, immediate discontinuation advised.
No pharmacokinetic data in pregnancy. No dose adjustment recommended based on available data, but therapeutic drug monitoring is advised if available due to altered volume of distribution and clearance during pregnancy.
Category C
Category C
Monitor blood pressure monthly; if uncontrolled, withhold LENVIMA. For proteinuria, check urine dipstick at baseline and periodically; if ≥2+, hold dose until resolves. Manage diarrhea aggressively with loperamide and hydration; dose interruption may be needed. Avoid concomitant strong CYP3A4 inducers or inhibitors; adjust dose per PI. In patients with thyroid cancer, monitor TSH monthly and adjust thyroid hormone as LENVIMA can cause hypothyroidism.
Ponlimsi (ponatinib) is a third-generation tyrosine kinase inhibitor (TKI) targeting BCR-ABL, including T315I mutation. Monitor for arterial thrombotic events (cardiovascular, cerebrovascular, peripheral vascular) and hepatotoxicity. Check liver function tests (LFTs) at baseline and monthly. Pancreatitis risk: monitor lipase and amylase. Use with caution in patients with history of vascular disease or diabetes. Dose reduction recommended for moderate hepatic impairment. Do not use with strong CYP3A4 inducers or inhibitors.
Take LENVIMA at the same time each day with or without food.Do not open or crush capsules; swallow whole with water.Notify your doctor immediately if you experience severe diarrhea, nausea, vomiting, or decreased appetite.Measure your blood pressure regularly and report high readings.Report any signs of infection, including fever, chills, or sore throat.Women of childbearing age should use effective contraception during treatment and for at least 30 days after the last dose.Avoid breastfeeding during treatment and for at least 1 week after the last dose.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.Report any signs of liver problems: yellowing of skin/eyes, dark urine, or severe nausea/vomiting.Seek immediate medical attention if you experience chest pain, sudden shortness of breath, leg swelling, or focal neurologic symptoms.Avoid grapefruit and grapefruit juice during treatment.Use effective contraception during and for at least 1 month after stopping treatment.